Find clinical trials

This study is looking at whether a medicine called tranexamic acid can help reduce the risk of intracranial haemorrhage (ICH) recurrence in Cerebral Amyloid Angiopathy (CAA).

The purpose of this pre-screening study is to identify people who may be eligible for future clinical trials that test new drugs for Alzheimer’s disease (AD). Participants will be asked to perform a memory test and give a blood sample for the assessment of pTau217 blood biomarker that has been developed to help identify people who are likely to have AD. Participants will not receive any medication or therapeutic intervention in this study.

This trial aims to investigate the safety and efficacy of Multiple Subcutaneous Doses of TRB-061 in patients with moderate-to-severe Atopic Dermatitis. Participants will receive doses of study treatment for up to 6 months (24 months). This would include administering doses of study treatment (TRB-061 24mg or 50mg subcutaneous injections) or placebo every 4 weeks over 12 weeks in period 1. In period 2, another 4 doses of treatment with increased dose of 50mg, will be given over 12 weeks to all participants, including those who received placebo in period 1. Participants are expected to visit study clinic 16 times during trial.

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology.

JNJ-79635322 (BCMAxGPRC5DxCD3) is a novel immunoglobulin G1 trispecific antibody targeting the T-cell receptor (CD3 portion) with 1 binding arm and 2 plasma cell target antigen binding domains (BCMA and GPRC5D). The primary objective is to compare the efficacy of JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody (Teclistamab), based on dual primary endpoints of ORR and PFS, in participants with RRMMwho have received at least 3 prior lines of therapy including a PI, an IMiD, and an anti-CD38 antibody.

Based on the established activity of Tebentafusp, and the promising action of Roginolisib, this trial combines the two drugs from cycle 4 onwards in patients with metastatic uveal melanoma.

The purpose of this study is to compare the effects, good or bad, of trontinemab versus placebo on participants with AD. In this study, participants will get either trontinemab or placebo. Participants aged 50 - 90 years (inclusive) with early symptomatic AD will be eligible for inclusion. The effects of trontinemab versus placebo on clinical progression of AD will be evaluated through cognitive assessment and imaging.